Jesus E. Talavera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jesus E. Talavera has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ariana Alessandra Córdova Salazar
Institute of Biomedical Sciences Research, Ricardo Palma University, Lima 15039, Peru
1 shared publication - Cristhian Gonzales-Rospigliosi
Institute of Biomedical Sciences Research, Ricardo Palma University, Lima 15039, Peru
1 shared publication - Henry Leonidas Gomez
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
1 shared publication - Jhony Alberto De La Cruz Vargas
Instituto de Investigaciones en Ciencias Biomédicas (INICIB), Universidad Ricardo Palma, Lima, Peru
1 shared publication - Rafael Pichardo-Rodriguez
Institute of Biomedical Sciences Research, Ricardo Palma University, Lima 15039, Peru
1 shared publication
Latest Publications
- Open Access
- 11 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 344
Prognostic Relevance of Inflammatory Cytokines Il-6 and TNF-Alpha in Patients with Breast Cancer: A Systematic Review and Meta-Analysis
Although cytokines mediate inflammation and inflammation facilitates cancer progression, few studies have evaluated the association between specific cytokines and the prognostic value of breast cancer. Therefore, this study aims to address the following question: What is the prognostic relevance of serum IL-6 and TNF-alpha levels on overall survival and treatment response in women with breast cancer? A systematic review and meta-analysis of cohort studies was conducted. The databases consulted included PubMed/Medline, Web of Science, and EMBASE. A total of 1748 articles were identified, of which 10 were included in the review. A significant association was found between elevated levels of IL-6 and TNF-alpha with poor overall survival and poor treatment response. The meta-analysis showed an HR of 3.74 (95% CI: 1.84–7.6) for elevated IL-6 with high heterogeneity (I2: 61%; p = 0.07) and an HR of 3.13 (95% CI: 1.57–6.23) for TNF-alpha with low heterogeneity (I2: 0%; p = 0.9). The overall response rate was 75% (95% CI: 31–100%; I2: 92%). In conclusion, IL-6 and TNF-alpha emerge as prognostic inflammatory biomarkers in women with breast cancer and are associated with poor survival and poor treatment response. This study highlights the need to establish an international consensus on cutoff points and standardized determination methods to implement these biomarkers in clinical practice.
- 11 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 344
Open AccessPrognostic Relevance of Inflammatory Cytokines Il-6 and TNF-Alpha in Patients with Breast Cancer: A Systematic Review and Meta-Analysis
Although cytokines mediate inflammation and inflammation facilitates cancer progression, few studies have evaluated the association between specific cytokines and the prognostic value of breast cancer. Therefore, this study aims to address the following question: What is the prognostic relevance of serum IL-6 and TNF-alpha levels on overall survival and treatment response in women with breast cancer? A systematic review and meta-analysis of cohort studies was conducted. The databases consulted included PubMed/Medline, Web of Science, and EMBASE. A total of 1748 articles were identified, of which 10 were included in the review. A significant association was found between elevated levels of IL-6 and TNF-alpha with poor overall survival and poor treatment response. The meta-analysis showed an HR of 3.74 (95% CI: 1.84–7.6) for elevated IL-6 with high heterogeneity (I2: 61%; p = 0.07) and an HR of 3.13 (95% CI: 1.57–6.23) for TNF-alpha with low heterogeneity (I2: 0%; p = 0.9). The overall response rate was 75% (95% CI: 31–100%; I2: 92%). In conclusion, IL-6 and TNF-alpha emerge as prognostic inflammatory biomarkers in women with breast cancer and are associated with poor survival and poor treatment response. This study highlights the need to establish an international consensus on cutoff points and standardized determination methods to implement these biomarkers in clinical practice.